Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cantrixil

Small molecule · developed by Kazia Therapeutics

Phase 1 Most advanced trial (none active)
KZIA Developer
1 Registered trials

What is Cantrixil?

Cantrixil is an agent given by intraperitoneal injection at weekly doses escalated across several dose levels in a Part A dose-escalation study. It is studied in ovarian, fallopian tube and peritoneal neoplasms, alone and then with combination chemotherapy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Oncology
Developer
Kazia Therapeutics Limited (KZIA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
5DVS457HEG

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02903771 Phase 1 Ovarian Neoplasms Completed KZIA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms

More from Kazia Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KZIA page.

Follow KZIA, the company behind Cantrixil

See KZIA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KZIA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.